Skip to main content
Top
Published in: BMC Musculoskeletal Disorders 1/2014

Open Access 01-12-2014 | Research article

Rheumatologists lack confidence in their knowledge of cannabinoids pertaining to the management of rheumatic complaints

Authors: Mary-Ann Fitzcharles, Peter A Ste-Marie, Daniel J Clauw, Shahin Jamal, Jacob Karsh, Sharon LeClercq, Jason J McDougall, Yoram Shir, Kam Shojania, Zach Walsh

Published in: BMC Musculoskeletal Disorders | Issue 1/2014

Login to get access

Abstract

Background

Arthritis pain is reported as one of the most common reasons for persons using medical herbal cannabis in North America. “Severe arthritis” is the condition justifying legal use of cannabis in over half of all authorizations in Canada, where cannabis remains a controlled substance. As champions for the care of persons with arthritis, rheumatologists must be knowledgeable of treatment modalities both traditional and non-traditional, used by their patients. As study of cannabinoid molecules in medicine is recent, we have examined the confidence in the knowledge of cannabinoids expressed by Canadian rheumatologists.

Methods

The confidence of rheumatologists in their knowledge of cannabinoid molecules and mechanisms relevant to rheumatology, and their ability to advise patients about cannabinoid treatments was recorded by an online questionnaire circulated via email to the entire Canadian Rheumatology Association membership.

Results

Over three quarters of the 128 respondents lacked confidence in their knowledge of cannabinoid molecules. While 45% of respondents believed there was no current role for cannabinoids in rheumatology patient care, only 25% supported any use of herbal cannabis. With 70% never having previously prescribed or recommended any cannabinoid treatment, uncertainty regarding good prescribing practices was prevalent. Concerns about risks of cannabis use were in line with the current literature.

Conclusions

Rheumatologists lacked confidence in their knowledge of cannabinoid molecules in general and in their competence to prescribe any cannabinoid for rheumatic complaints. In line with this uncertainty, there is reticence to prescribe cannabinoid preparations for rheumatology patients. Guidance is required to inform rheumatologists on the evidence regarding cannabinoids.
Literature
1.
go back to reference Robson P: Abuse potential and psychoactive effects of delta-9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine. Expert Opin Drug Saf. 2011, 10 (5): 675-685.CrossRefPubMed Robson P: Abuse potential and psychoactive effects of delta-9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine. Expert Opin Drug Saf. 2011, 10 (5): 675-685.CrossRefPubMed
2.
go back to reference Aggarwal SK, Carter GT, Sullivan MD, ZumBrunnen C, Morrill R, Mayer JD: Characteristics of patients with chronic pain accessing treatment with medical cannabis in Washington State. J Opioid Manag. 2009, 5 (5): 257-286.PubMed Aggarwal SK, Carter GT, Sullivan MD, ZumBrunnen C, Morrill R, Mayer JD: Characteristics of patients with chronic pain accessing treatment with medical cannabis in Washington State. J Opioid Manag. 2009, 5 (5): 257-286.PubMed
3.
go back to reference Office of the Information Commissioner of Canada: Information Request (ATI 2013–00282) Under the Access to Information Act. 2013 Office of the Information Commissioner of Canada: Information Request (ATI 2013–00282) Under the Access to Information Act. 2013
4.
go back to reference Eggertson L: New medical marijuana regulations shift onus to doctors to prescribe. CMAJ. 2013, 2: 2- Eggertson L: New medical marijuana regulations shift onus to doctors to prescribe. CMAJ. 2013, 2: 2-
6.
go back to reference Fitzcharles MA, McDougall J, Ste-Marie PA, Padjen I: Clinical implications for cannabinoid use in the rheumatic diseases: potential for help or harm?. Arthritis Rheum. 2012, 64 (8): 2417-2425. doi: 10.1002/art.34522CrossRefPubMed Fitzcharles MA, McDougall J, Ste-Marie PA, Padjen I: Clinical implications for cannabinoid use in the rheumatic diseases: potential for help or harm?. Arthritis Rheum. 2012, 64 (8): 2417-2425. doi: 10.1002/art.34522CrossRefPubMed
7.
go back to reference Fitzcharles MA, Clauw DJ, Ste-Marie PA, Shir Y: The dilemma of medical marijuana use by rheumatology patients. Arthritis Care Res. 2014, 66 (6): 797-801.CrossRef Fitzcharles MA, Clauw DJ, Ste-Marie PA, Shir Y: The dilemma of medical marijuana use by rheumatology patients. Arthritis Care Res. 2014, 66 (6): 797-801.CrossRef
9.
go back to reference Fitzcharles M-A, Almahrezi A, Shir Y: Pain: understanding and challenges for the rheumatologist. Arthritis Rheum. 2005, 52 (16329076): 3685-3692.CrossRefPubMed Fitzcharles M-A, Almahrezi A, Shir Y: Pain: understanding and challenges for the rheumatologist. Arthritis Rheum. 2005, 52 (16329076): 3685-3692.CrossRefPubMed
10.
go back to reference Goldenberg DL, Clauw DJ, Fitzcharles MA: New concepts in pain research and pain management of the rheumatic diseases. Semin Arthritis Rheum. 2011, 41 (3): 319-334.CrossRefPubMed Goldenberg DL, Clauw DJ, Fitzcharles MA: New concepts in pain research and pain management of the rheumatic diseases. Semin Arthritis Rheum. 2011, 41 (3): 319-334.CrossRefPubMed
12.
go back to reference Ware MA, Adams H, Guy GW: The medicinal use of cannabis in the UK: results of a nationwide survey. Int J Clin Pract. 2005, 59 (3): 291-295.CrossRefPubMed Ware MA, Adams H, Guy GW: The medicinal use of cannabis in the UK: results of a nationwide survey. Int J Clin Pract. 2005, 59 (3): 291-295.CrossRefPubMed
13.
go back to reference Kondrad E, Reid A: Colorado family physicians’ attitudes toward medical marijuana. J Am Board Fam Med. 2013, 26 (1): 52-60.CrossRefPubMed Kondrad E, Reid A: Colorado family physicians’ attitudes toward medical marijuana. J Am Board Fam Med. 2013, 26 (1): 52-60.CrossRefPubMed
Metadata
Title
Rheumatologists lack confidence in their knowledge of cannabinoids pertaining to the management of rheumatic complaints
Authors
Mary-Ann Fitzcharles
Peter A Ste-Marie
Daniel J Clauw
Shahin Jamal
Jacob Karsh
Sharon LeClercq
Jason J McDougall
Yoram Shir
Kam Shojania
Zach Walsh
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Musculoskeletal Disorders / Issue 1/2014
Electronic ISSN: 1471-2474
DOI
https://doi.org/10.1186/1471-2474-15-258

Other articles of this Issue 1/2014

BMC Musculoskeletal Disorders 1/2014 Go to the issue